Psychedelics & Cannabis

Recent trials reveal LSD's potential to significantly reduce anxiety symptoms in GAD, offering a promising alternative to traditional treatments.

Rick Doblin discusses FDA's recent feedback on MDMA-assisted therapy for PTSD, emphasizing transparency and the therapy's potential in clinical practice.

Cannabis use among older adults surges as they seek relief from pain and anxiety, prompting clinicians to navigate complex treatment challenges.

Incannex Healthcare shared positive data from its phase 2 clinical trial of PSX-001, a psilocybin-assisted psychotherapy treatment for generalized anxiety disorder.

PharmaTher's KETARx gains FDA approval, paving the way for innovative ketamine treatments in pain management and mental health disorders.

Ketamine-assisted psychotherapy has transformative potential as a groundbreaking approach to mental health that enhances healing through psychedelic experiences.

New research reveals ketamine's safe use for treating eating disorders, offering hope for patients with comorbid treatment-resistant depression.

New clinical trial results reveal BPL-003's rapid and durable antidepressant effects, paving the way for innovative treatments in treatment-resistant depression.

Compass Pathways reports significant progress in psilocybin research, showing promise for treatment-resistant depression in a pivotal phase 3 trial.

Ketamine-assisted psychotherapy: enhancing healing through emotional support and insight-driven therapy for depression.

What should you know about the lesser known psychedelics? Clinical insights from Jacob Perlson, MD, MPH, at the APA Annual Meeting.

Combination therapy of TMS and ketamine could enhance brain perfusion and neuroplasticity.

The first patient has been dosed in MindMed’s phase 3 Emerge study evaluating the efficacy of MM120 ODT.

A single dose of psilocybin was associated with a significant and sustained reduction in depressive symptoms and possible improvement of PTSD and burnout experienced by clinicians from the front line of the COVID-19 pandemic.

Dennis S. Charney, MD, discussed the importance of trying and risking failure when studying new potential treatments, as well as the future of treating depression.

Dennis S. Charney, MD, celebrates the 40th anniversary of Psychiatric Times discussing the history of psychiatry and where he hopes the future lies.

Here are highlights from this week in Psychiatric Times, including a special report on psychiatric symptoms of celiac disease and the potential dangers of cannabis use in older patients.

Learn more about the need for closer collaboration between psychiatry and cannabis research to explore its therapeutic potential, mitigate risks, and advance evidence-based mental health treatments.

Why are older patients turning to cannabis for symptom relief?

Celebrate Psychiatric Times’ 40th anniversary with a look back at some of our previous covers.

Cannabis use disorder and schizophrenia both peak in prevalence around the same age. Is there a cause-and-effect relationship?

Mark Viner, MD, shares his thoughts on the place cannabis holds in psychiatry and addressing the stigma cannabis faces.

As cannabis transitions from an illicit drug to a multi-billion-dollar industry, psychiatry faces both challenges and opportunities in exploring its therapeutic potential while balancing the risks.